Albireo Pharma (NASDAQ:ALBO) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Wednesday.
A number of other equities research analysts also recently issued reports on the stock. Wedbush restated a “buy” rating and issued a $69.00 target price on shares of Albireo Pharma in a report on Wednesday, October 17th. Cowen restated a “buy” rating on shares of Albireo Pharma in a report on Wednesday, November 14th. ValuEngine downgraded shares of Albireo Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Needham & Company LLC restated a “buy” rating and issued a $50.00 target price on shares of Albireo Pharma in a report on Tuesday, November 13th. Finally, Zacks Investment Research cut shares of Albireo Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, November 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $51.25.
Albireo Pharma stock opened at $26.50 on Wednesday. Albireo Pharma has a 1 year low of $19.10 and a 1 year high of $39.35. The company has a market capitalization of $317.44 million, a P/E ratio of -8.41 and a beta of 1.74.
Albireo Pharma (NASDAQ:ALBO) last released its earnings results on Tuesday, November 13th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.20). The company had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $1.55 million. As a group, equities analysts anticipate that Albireo Pharma will post -3.7 EPS for the current year.
In other Albireo Pharma news, insider Ronald Harold Wilfred Cooper purchased 1,026 shares of Albireo Pharma stock in a transaction on Tuesday, November 13th. The shares were purchased at an average cost of $25.02 per share, with a total value of $25,670.52. Following the completion of the transaction, the insider now directly owns 7,760 shares in the company, valued at approximately $194,155.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 3.60% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. Prosight Management LP acquired a new position in Albireo Pharma during the third quarter valued at approximately $5,369,000. Renaissance Technologies LLC lifted its position in Albireo Pharma by 16.2% during the second quarter. Renaissance Technologies LLC now owns 107,366 shares of the biopharmaceutical company’s stock valued at $3,811,000 after buying an additional 14,934 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Albireo Pharma by 205.0% during the second quarter. Bank of New York Mellon Corp now owns 32,263 shares of the biopharmaceutical company’s stock worth $1,145,000 after purchasing an additional 21,685 shares in the last quarter. BlackRock Inc. lifted its position in shares of Albireo Pharma by 11.4% during the third quarter. BlackRock Inc. now owns 584,177 shares of the biopharmaceutical company’s stock worth $19,255,000 after purchasing an additional 59,901 shares in the last quarter. Finally, Chicago Capital LLC lifted its position in shares of Albireo Pharma by 18.9% during the third quarter. Chicago Capital LLC now owns 160,248 shares of the biopharmaceutical company’s stock worth $5,282,000 after purchasing an additional 25,500 shares in the last quarter. 64.84% of the stock is currently owned by hedge funds and other institutional investors.
About Albireo Pharma
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Featured Article: Asset Allocation
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.